Extramedullary Disease in Multiple Myeloma Clinical Trials in Buffalo, New York

Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease